HPLC-MS comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-07. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water; stock solutions use organic solvent. |
| Storage | -20°C, desiccated, protected from light | Limits hydrolysis and photodegradation. |
| Analytical method | HPLC-UV/MS | Used for identity and purity assessment. |
| Synonyms | SR9009, Stenabolic | Naming varies by supplier. |
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Parmotrema perlatum typically grows in areas with ample light, favouring neutral to slightly acidic-barked broad-leaved trees. It is commonly found on siliceous rocks and walls, as well as mossy coastal rocks, generally growing in places with moderate to strong sunlight. In the Great Smoky Mountains National Park in the United States, Parmotrema perlatum is especially abundant on branches in humid, high-elevation habitats. Similarly, in East Africa, it grows in the misty environments of inselbergs, montane forests, and Erica-dominated habitats, typically found between 1,400 and 3,100 m (4,600 and 10,200 ft) above sea level. The species is globally distributed, found in both temperate and tropical regions. It has been reported across numerous European countries including Austria, Belgium, the Czech Republic, France, Germany, Great Britain, Ireland, Italy, Luxembourg, the Netherlands, Portugal, Scandinavia, Slovakia, Spain, and Ukraine. Although it is rare in Eastern Europe, it is widely distributed in both the Asian and European parts of Russia. Beyond Europe, it is also present in Macaronesia, Africa, Australia, North America, and South America. Its Asian distribution includes India, Japan, Taiwan, and South Korea. Although it has historically been recorded in Nepal and Sri Lanka, these reports are considered tentative due to shifting species concepts and possible confusion with the lookalike Parmotrema pseudonilgherrense.
For comparison with lower dosages, the suppression of circulating testosterone levels in men with a dosage of 100 mg/day oral CPA was 77% and with a dosage of 300 mg/week intramuscular CPA was 76%. Dosages of CPA of 12.5 to 25 mg/day have been used as a maintenance dosage for testosterone suppression in men with sexual deviance after initial administration of higher CPA dosages, without recurrence of symptoms. CPA is generally able to maximally suppress circulating testosterone levels by 70 to 80% in men. However, in spite of strong suppression of testosterone levels, CPA, at least by itself (e.g., without estrogen), is not usually able to reduce testosterone levels into the castrate/female range (<50 ng/dL) at any dosage, and testosterone levels generally remain just above it at levels of roughly 50 to 200 ng/dL. However, studies have reported that a very high dosage of CPA of 300 mg/day may suppress testosterone levels to around 50 ng/dL in men. CPA also suppresses estradiol levels in men, with one study finding about a 65% decrease in estradiol levels (from about 27 pg/mL to around 10 pg/mL) with 100 mg/day CPA. CPA has been found to maximally suppress testosterone and estradiol levels in young men within 7 days of continuous administration. Following discontinuation of CPA, the recovery of testosterone levels is variable and may require 14 days to 6 months for completion. An escape or recovery phenomenon, in which testosterone levels increase over time, has been observed with long-term CPA monotherapy.
Sen also holds a courtesy appointment as Professor of Biomedical Engineering at the Weldon School of Biomedical Engineering, Purdue University. His research continues to focus on nanotechnology-based strategies for tissue regeneration. During the COVID-19 pandemic, Sen's team demonstrated that electrical fields can inactivate coronavirus, leading to the development of electroceutical fabrics for personal protective equipment. Following a successful pilot study on wound biofilm infection at the San Antonio Military Medical Center, the technology was funded by the U.S. Department of Defense for testing on war wounds in Ukraine. In 2025, the NIDDK Diabetic Foot Consortium published its first completed clinical study—the TEWL study. Sen served as lead principal investigator for this landmark trial, which proposed redefining the clinical wound closure endpoint. The study introduced transepidermal water loss (TEWL) as a biomarker for wound recurrence, highlighting that wounds appearing closed but lacking barrier function—termed “invisible wounds”—carry a higher risk of reopening. This paradigm shift emphasizes that wound closure must include restoration of barrier function, a critical metric for clinical decision-making, regulatory approval, and reimbursement in wound care.
Sources: en.wikipedia.org
To solve many of the above problems, as well as continuing the process of self-determination that was accompanying the dismantling of the Empire, it was proposed that Aden Colony should form a federation with the protectorates of East and West Aden. It was hoped that this would lessen Arab calls for complete independence, while still allowing British control of foreign affairs and the BP refinery at Little Aden to continue. It was the hope of the government of Harold Macmillan that creating a federation that would be dominated by the traditional sultans would allow for indirect British control as he wrote in his diary that his government planned to use "the Sultans to help us keep the colony and its essential defence facilities". However, the population of Aden was urban, well educated, secular and generally left-wing while the population of the protectorates were rural, mostly illiterate, religious and generally conservative, making the proposed federation a mismatch.
By using QDs, only the necessary colors for ideal images are contained in the screen. The first commercial application of quantum dots was the Sony XBR X900A series of flat panel televisions released in 2013. In June 2006, QD Vision announced technical success in making a proof-of-concept quantum dot display and show a bright emission in the visible and near infrared region of the spectrum. A QD-LED integrated at a scanning microscopy tip was used to demonstrate fluorescence near-field scanning optical microscopy (NSOM) imaging.
Unlike classes I and II, Class III molecules have physiological roles and are encoded between classes I and II on the short arm of human chromosome 6. Class III molecules include several secreted proteins with immune functions: components of the complement system (such as C2, C4, and B factor), cytokines (such as TNF-α, LTA, and LTB), and heat shock proteins.
Sources: en.wikipedia.org
In October and December 1994, King Crimson recorded their eleventh studio album, Thrak, at Peter Gabriel's Real World Studios. Containing revised versions of the songs from Vrooom, plus some new tracks, the album was described by Q magazine as having "jazz-scented rock structures, characterised by noisy, angular, exquisite guitar interplay" and an "athletic, ever-inventive rhythm section", while being in tune with the sound of alternative rock of the mid-1990s. Examples of the band's efforts to integrate their multiple elements could be heard on the accessible (but complex) songs "Dinosaur" and "Sex Sleep Eat Drink Dream", the more straightforward ballad "One Time", as well as "Radio I" and "Radio II"- a pair of Fripp's Soundscapes instrumentals. King Crimson resumed touring in 1995 and into 1996. Dates from October and November 1995 were recorded and released on the live album Thrakattak in May 1996, which is an hour of improvised music integrating sections from performances of Thrak's title track in the United States and Japan as mixed and arranged into a single work by David Singleton. A more conventional live recording from the period was later made available as the double CD release Vrooom Vrooom (2001), while a full 1995 concert was released on VHS in 1996 as Live in Japan and re-released on DVD in 1999 as Déjà Vrooom. The double trio would be further honoured by the Thrak (1994–1997) box set in 2015. The band began rehearsing again in May 1997 in Nashville, Tennessee.
== Education == Uhlmann was educated at the University of Tübingen where he was awarded a PhD in 1997. During his PhD, he worked with Jerard Hurwitz at the Memorial Sloan Kettering Cancer Center in New York City.
The research was taken up by Wilhelm Kühne, who named the pigment rhodopsin, also known as "visual purple." Kühne confirmed that rhodopsin is extremely sensitive to light, and thus enables vision in low-light conditions, and that it was this chemical decomposition that stimulated nerve impulses to the brain. Research stalled until after identification of "fat-soluble vitamin A" as a dietary substance found in milkfat but not lard, would reverse night blindness and xerophthalmia. In 1925, Fridericia and Holm demonstrated that vitamin A deficient rats were unable to regenerate rhodopsin after being moved from a light to a dark room.
Sources: en.wikipedia.org
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.
The solid is generally kept cold, dry, and protected from light. Solutions are often frozen in single-use aliquots to reduce repeated freeze-thaw cycles.
It indicates a material sold for laboratory study, not for human use. The label does not guarantee pharmaceutical purity, sterility, or regulatory approval.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.